307 related articles for article (PubMed ID: 22413863)
1. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).
Flygare JA; Beresini M; Budha N; Chan H; Chan IT; Cheeti S; Cohen F; Deshayes K; Doerner K; Eckhardt SG; Elliott LO; Feng B; Franklin MC; Reisner SF; Gazzard L; Halladay J; Hymowitz SG; La H; LoRusso P; Maurer B; Murray L; Plise E; Quan C; Stephan JP; Young SG; Tom J; Tsui V; Um J; Varfolomeev E; Vucic D; Wagner AJ; Wallweber HJ; Wang L; Ware J; Wen Z; Wong H; Wong JM; Wong M; Wong S; Yu R; Zobel K; Fairbrother WJ
J Med Chem; 2012 May; 55(9):4101-13. PubMed ID: 22413863
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K
ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540
[TBL] [Abstract][Full Text] [Related]
3. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
Sun H; Lu J; Liu L; Yang CY; Wang S
ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
[TBL] [Abstract][Full Text] [Related]
5. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
[TBL] [Abstract][Full Text] [Related]
6. Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins.
Sun H; Lu J; Liu L; Yi H; Qiu S; Yang CY; Deschamps JR; Wang S
J Med Chem; 2010 Sep; 53(17):6361-7. PubMed ID: 20684551
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).
Hennessy EJ; Adam A; Aquila BM; Castriotta LM; Cook D; Hattersley M; Hird AW; Huntington C; Kamhi VM; Laing NM; Li D; MacIntyre T; Omer CA; Oza V; Patterson T; Repik G; Rooney MT; Saeh JC; Sha L; Vasbinder MM; Wang H; Whitston D
J Med Chem; 2013 Dec; 56(24):9897-919. PubMed ID: 24320998
[TBL] [Abstract][Full Text] [Related]
8. WX20120108, a novel IAP antagonist, induces tumor cell autophagy via activating ROS-FOXO pathway.
Ding R; Wang X; Chen W; Li Z; Wei AL; Wang QB; Nie AH; Wang LL
Acta Pharmacol Sin; 2019 Nov; 40(11):1466-1479. PubMed ID: 31316176
[TBL] [Abstract][Full Text] [Related]
9. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
Bockbrader KM; Tan M; Sun Y
Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
[TBL] [Abstract][Full Text] [Related]
10. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
[TBL] [Abstract][Full Text] [Related]
11. Recognition of Smac-mimetic compounds by the BIR domain of cIAP1.
Cossu F; Malvezzi F; Canevari G; Mastrangelo E; Lecis D; Delia D; Seneci P; Scolastico C; Bolognesi M; Milani M
Protein Sci; 2010 Dec; 19(12):2418-29. PubMed ID: 20954235
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
[TBL] [Abstract][Full Text] [Related]
13. Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold.
Cohen F; Alicke B; Elliott LO; Flygare JA; Goncharov T; Keteltas SF; Franklin MC; Frankovitz S; Stephan JP; Tsui V; Vucic D; Wong H; Fairbrother WJ
J Med Chem; 2009 Mar; 52(6):1723-30. PubMed ID: 19228017
[TBL] [Abstract][Full Text] [Related]
14. Structural insight into inhibitor of apoptosis proteins recognition by a potent divalent smac-mimetic.
Cossu F; Milani M; Vachette P; Malvezzi F; Grassi S; Lecis D; Delia D; Drago C; Seneci P; Bolognesi M; Mastrangelo E
PLoS One; 2012; 7(11):e49527. PubMed ID: 23166698
[TBL] [Abstract][Full Text] [Related]
15. Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.
Kester RF; Donnell AF; Lou Y; Remiszewski SW; Lombardo LJ; Chen S; Le NT; Lo J; Moliterni JA; Han X; Hogg JH; Liang W; Michoud C; Rupert KC; Mischke S; Le K; Weisel M; Janson CA; Lukacs CM; Fretland AJ; Hong K; Polonskaia A; Gao L; Li S; Solis DS; Aguilar D; Tardell C; Dvorozniak M; Tannu S; Lee EC; Schutt AD; Goggin B
J Med Chem; 2013 Oct; 56(20):7788-803. PubMed ID: 24093940
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule SMAC mimetics as new cancer therapeutics.
Bai L; Smith DC; Wang S
Pharmacol Ther; 2014 Oct; 144(1):82-95. PubMed ID: 24841289
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.
Oost TK; Sun C; Armstrong RC; Al-Assaad AS; Betz SF; Deckwerth TL; Ding H; Elmore SW; Meadows RP; Olejniczak ET; Oleksijew A; Oltersdorf T; Rosenberg SH; Shoemaker AR; Tomaselli KJ; Zou H; Fesik SW
J Med Chem; 2004 Aug; 47(18):4417-26. PubMed ID: 15317454
[TBL] [Abstract][Full Text] [Related]
18. Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain.
Donnell AF; Michoud C; Rupert KC; Han X; Aguilar D; Frank KB; Fretland AJ; Gao L; Goggin B; Hogg JH; Hong K; Janson CA; Kester RF; Kong N; Le K; Li S; Liang W; Lombardo LJ; Lou Y; Lukacs CM; Mischke S; Moliterni JA; Polonskaia A; Schutt AD; Solis DS; Specian A; Taylor RT; Weisel M; Remiszewski SW
J Med Chem; 2013 Oct; 56(20):7772-87. PubMed ID: 24083782
[TBL] [Abstract][Full Text] [Related]
19. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP.
Vucic D; Franklin MC; Wallweber HJ; Das K; Eckelman BP; Shin H; Elliott LO; Kadkhodayan S; Deshayes K; Salvesen GS; Fairbrother WJ
Biochem J; 2005 Jan; 385(Pt 1):11-20. PubMed ID: 15485396
[TBL] [Abstract][Full Text] [Related]
20. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
